GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...

GSK sales hampered by slump in demand for key vaccine - The drugmaker said sales of Arexvy fell sharply in the third quarter, ...

Biogen, UCB report phase 3 lupus win, justifying risky bet on asset that failed earlier trial GSK was the first to market when its BLyS-specific inhibitor Benlysta was approved by the FDA in 2011. It ...

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

GSK is delivering consistent financial performance ... Cabenuva grew 40%, driven by patient preference and proven and durable efficacy. The medicine now holds a market share of 5% or more in ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...